BioWorld

Jan. 7, 2002

Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints. Read More

Aurora, Allergan Expand Work To Include GPCR Screening

Industry, Academia Knock Out Immune Rejection Gene From Porcine Xenotransplant Grafts

Acadia Partners With Amgen To Discover Small-Molecule Drugs

Other News To Note

3-D Pharma, J&J Collaborate On Small-Molecule Drug Discovery

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026